BASIC AND CLINICAL STUDIES ON CEFCLIDIN FOR SURGICAL APPLICATION
スポンサーリンク
概要
- 論文の詳細を見る
Basic and clinical studies on cefclidin (CFCL), a newly developed injectable cephem antibiotic, were carried out in the field of surgery, and the following results were obtained.<BR>1. Antibacterial activity MIC<SUB>50</SUB>/MIC<SUB>90</SUB> (μg/ml) of CFCL against clinical isolates from surgical infections, of <I>Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa</I>, were 12.5/100, 0.1/0.78., 0.1/0.39, and 3.13/12.5, respectively. Antibacterial activity of CFCL against <I>S.aureus</I> was as strong as those of ceftazidime (CAZ). However, the activity of CFCL against <I>E.coli</I> and <I>K.pneumoniae</I>, was equal or superior to activities of CAZ, and CFCL showed the most powerful activity against <I>P.aeruginosa</I> among all drugs tested.<BR>2. Penetration into bile and ascites: Biliary levels of CFCL were determined in 6 patients. The mean peak level of CFCL after the administration at 1 hour after dosing of 1g (i.v.) was 17.4μg/ml. No accumulation of CFCL was recognized in bile after the repeat administration. Meanwhile, the mean peak level of CFCL in ascites on for 5 patients reached 30.6μg/ml after the dosing of 1g (i.v.)<BR>3. Clinical results: CFCL was administered to 24 patients with surgical infections. The clinical responses were excellent in 3 cases, good in 11, fair in 6, poor in 3, unevaluable in 1 and the overall efficacy rate was 61%. Bacteriological responses were eradicated in 4 cases, partially eradicated in 4, persisted in 2, replaced in 5 and the overall eradicated rate was 60%.<BR>No adverse reaction was noted. Abnormal laboratory findings were recognized in 6 cases but these abnormal changes returned to normal ranges after the termination of dosing.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.